G-CSF in the Treatment of Toxic Epidermal Necrolysis
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis.
This is a prospective randomized controlled trial.
Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of
G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at
admission and will be followed until 3 months after discharge.